2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Veit Bücklein et al.|Blood|2021Cited by 714
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Hervé Dombret, Emmanuel Raffoux et al.|The Lancet Haematology|2016Cited by 431
Cooperating gene mutations in acute myeloid leukemia: a review of the literatureAline Renneville, Claude Preudhomme, Christophe Roumier et al.|Leukemia|2008Cited by 348
High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21Claude Preudhomme, Pierre Fenaux, Delphine Warot-Loze et al.|Blood|2000Cited by 254
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Michael Heuser, Peter J.M. Valk et al.|Blood|2025Cited by 22